These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28129893)

  • 1. A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer.
    Ehdaie B; Assel M; Benfante N; Malhotra D; Vickers A
    Eur Urol; 2017 Jun; 71(6):866-871. PubMed ID: 28129893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance.
    Goh AC; Kowalkowski MA; Bailey DE; Kazer MW; Knight SJ; Latini DM
    BJU Int; 2012 Jul; 110(2 Pt 2):E50-6. PubMed ID: 22145791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
    Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
    Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.
    Pang K; Fitch M; Ouellet V; Chevalier S; Drachenberg DE; Finelli A; Lattouf JB; So A; Sutcliffe S; Tanguay S; Saad F; Mes-Masson AM
    BMC Health Serv Res; 2018 Jun; 18(1):430. PubMed ID: 29884180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative study to understand guideline-discordant use of imaging to stage incident prostate cancer.
    Makarov DV; Sedlander E; Braithwaite RS; Sherman SE; Zeliadt S; Gross CP; Curnyn C; Shedlin M
    Implement Sci; 2016 Sep; 11(1):118. PubMed ID: 27590603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Factors That Influence How Physicians Discuss Active Surveillance With Low-Risk Prostate Cancer Patients: A Qualitative Study.
    Brooks JV; Ellis SD; Morrow E; Kimminau KS; Thrasher JB
    Am J Mens Health; 2018 Sep; 12(5):1719-1727. PubMed ID: 29973123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.
    Thomsen FB; Røder MA; Hvarness H; Iversen P; Brasso K
    Dan Med J; 2013 Feb; 60(2):A4575. PubMed ID: 23461989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
    Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
    Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
    Kim SP; Gross CP; Nguyen PL; Smaldone MC; Shah ND; Karnes RJ; Thompson RH; Han LC; Yu JB; Trinh QD; Ziegenfuss JY; Sun M; Tilburt JC
    Med Care; 2014 Jul; 52(7):579-85. PubMed ID: 24926704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance.
    Bellardita L; Rancati T; Alvisi MF; Villani D; Magnani T; Marenghi C; Nicolai N; Procopio G; Villa S; Salvioni R; Valdagni R
    Eur Urol; 2013 Jul; 64(1):30-6. PubMed ID: 23357351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial.
    Peabody JW; DeMaria LM; Tamondong-Lachica D; Florentino J; Czarina Acelajado M; Ouenes O; Richie JP; Burgon T
    BMC Urol; 2017 Jul; 17(1):51. PubMed ID: 28673277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of urologist experience on choosing active surveillance for prostate cancer.
    Chu WG; Kim BJ; Slezak J; Harrison TN; Gelfond J; Jacobsen SJ; Chien GW
    World J Urol; 2015 Nov; 33(11):1701-6. PubMed ID: 25761737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer.
    Bates AS; Kostakopoulos N; Ayers J; Jameson M; Todd J; Lukha R; Cymes W; Chasapi D; Brown N; Bhattacharya Y; Paterson C; Lam TBL
    Semin Oncol Nurs; 2020 Aug; 36(4):151045. PubMed ID: 32703714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer.
    Davison BJ; Goldenberg SL
    BJU Int; 2011 Dec; 108(11):1787-93. PubMed ID: 21507187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.